Federated Registry Data Scientist
Rhythm Pharmaceuticals3w ago
Hybrid in Madrid +3
The English-language job board for Spain
89,000+ live jobs
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with rare neuroendocrine diseases.
2 open
- Locations
- Madrid, Spain, Italy, Madrid; London; Paris; Amsterdam; Munich, UK, France, Netherlands, Germany, Spain, Italy, France
- Newest advert
- 27 days ago
- Level
- Senior+ for 1 of 2
- Locations
- Madrid, Spain, Italy, Madrid; London; Paris; Amsterdam; Munich, UK, France, Netherlands, Germany, Spain, Italy, France
- Newest advert
- 27 days ago
- Level
- Senior+ for 1 of 2
2 jobs
. Sorted by
Director, HR Business Partner, International
Rhythm Pharmaceuticals1mo ago
Madrid, Spain, Italy
About the company
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with rare neuroendocrine diseases. The company develops precision medicines targeting the MC4R pathway, with its lead product IMCIVREE approved for multiple indications. With over 400 employees across North America and Europe, Rhythm is expanding its international presence, including roles in Spain for hospital affairs and scientific affairs.
For International Professionals
- Rhythm Pharmaceuticals is headquartered in Boston's Back Bay neighborhood, easily accessible by public transportation.
- The company offers a competitive compensation and benefits package, including equity grants and an employee stock purchase plan.
- Rhythm has a fast-paced and collaborative work environment, with employees across North America and Europe.
- The company is expanding its international operations, with current openings in Spain for hospital affairs and scientific affairs roles.
- EU residents are provided with a privacy policy on data use, indicating compliance with EU data protection regulations.
Company History
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases. Its lead asset, IMCIVREE (setmelanotide), was FDA-approved in 2020 for obesity due to POMC and LEPR deficiency, with subsequent approvals for Bardet-Biedl syndrome in the US and Europe. The company has grown to over 400 employees across North America and Europe, with a robust clinical trials program.